40 results about "CD68" patented technology

The invention belongs to the technical field of tumor micro-immune environments, and particularly relates to a kit for detecting a tumor micro-environment, a detection method and application, the kit comprises rare metal element labeled monoclonal antibodies, the rare metal element labeled monoclonal antibodies comprise 115In-CD20, 139La-Histone H3, 142Nd-CD56, 144Nd-CD14, 146Nd-Vimentin, 148Nd-Pan-CK, 151Eu-CD31, 156Gd-CD4, 158Gd-E-Cadrin, 159Tb-CD68, 162Dy-CD8a, 166Er-CD45, 167Er-CD15, 170Er-CD3, 171Yb-CD11c and 209Bi-alpha-SMA, and the rare metal element labeled monoclonal antibodies comprise The invention can be used for simultaneously detecting and researching the quantity, positioning and spatial topological relation of each cell component in a tumor microenvironment, and provides a multi-immunofluorescence detection kit and method for ubiquitous epithelial differentiation-derived tumors based on an imaging mass spectrum flow technique. A plurality of biomarkers can be analyzed at the same time by using multiple immunohistochemical staining and rare earth metal tag signal detection technologies, so that the aim of performing high-dimensional analysis on a tumor microenvironment is fulfilled according to cell composition, functional state and cell-cell space interaction relationship.

The invention relates to a marker combination for predicting curative effect of melanoma anti-PD-1 immunotherapy and application of the marker combination. Specifically, more abundant and more accurate biomarkers (S100, CD68, CD3, CD20, PD-L1 and PD-1) related to the curative effect of the melanoma immunotherapy are obtained through co-localization of a plurality of biomarkers and spatial feature analysis, and a prediction model for evaluating the curative effect of the melanoma anti-PD-1 immunotherapy is prepared by using the biomarkers. The model has good sensitivity and specificity, and has a wide application prospect.

Methods for treating a patient having a solid tumor are disclosed, comprising: (a) obtaining a tumor sample from the patient; (b) assessing the sample for levels of biomarkers for at least one of innate immune cells and adaptive immune cells; and (c) administering an effective amount of an immunotherapy to the patient if the sample comprises elevated levels of CD68+ PD-L1+ macrophages and CD8+ T cells compared to control and / or elevated levels of CD20+ B cells compared to control and / or low levels of CD163 expression compared to control and PD-L1 expression of greater or equal to (≥) 50%.

Disclosed are methods for treating a patient having a solid tumor, the methods comprising: (a) obtaining a tumor sample from the patient; (b) evaluating the sample for the level of a biomarker for at least one of innate and adaptive immune cells; and (c) administering to the patient an effective amount of immunotherapy if the sample contains elevated levels of CD68+PD-L1+ macrophages and CD8+ T cells relative to a control and / or elevated levels of CD20+ B cells relative to a control and / or low levels of CD163 expression and 50% or greater (≧) PD-L1 expression relative to a control.

The invention discloses application of an mRNAs marker in early diagnosis of lung signet-ring cell carcinoma and a kit. The marker is a combination of C1QA, CRISPLD2, ROBO4, SPARCL1, SFTPB, LAMC3, FN1, EMP1, CD68, THBS1, PRG4, ICAM1, PODXL, KDM6B, ENPP2, KLF10 and THBD (tetrahydrofuran). According to the invention, FFPE cancer tissue of a patient with primary pulmonary signet ring cell carcinoma diagnosed by an existing detection means in clinic is used as a sample, para-carcinoma tissue is used as a control sample, mRNA expression profiles of the cancer tissue and the control tissue are detected by adopting an RNA sealing technology, and 17 differentially expressed mRNA markers are found by applying statistics and a machine learning method. Based on the 17 found markers, a risk scoring model with high sensitivity and specificity is constructed, and the sensitivity gt of the model to early-stage lung signet-ring cell carcinoma diagnosis; the specificity is gt; 89%.

The invention discloses application of MAT2A as an anti-inflammatory target spot in treatment of atherosclerosis. Research finds that in carotid plaque of a symptomatic atherosclerotic patient and aortic sinus lesions of an ApoE- / -mouse with advanced atherosclerotic plaque, the accumulation of methionine adenosine transferase 2A (MAT2A) in CD68 + macrophages is increased, an MAT2A inhibitor FIDAS-5 can play an inhibition role by combining with an MAT2A active site, and the use of the MAT2A inhibitor FIDAS-5 can be used for inhibiting the aortic sinus lesions of the ApoE- / -mouse with advanced atherosclerotic plaque. Further, inflammatory response of atherosclerosis patients is relieved, and the process of atherosclerosis is delayed The invention provides a new therapeutic target and technical means for the treatment of atherosclerosis.

The application belongs to the technical field of biotechnology, and particularly relates to a marker for prognosis evaluation of acute myeloid leukemia and application thereof, wherein the marker is HCK-positive mono-like cells, the HCK-positive mono-like cells are determined by co-positivity of antigens CD163, antigen CD68, antigen FCN1 and antigen HCK, and the application provides a marker with high sensitivity, strong specificity and good universality, which is used for detecting adult acute myeloid leukemia bone marrow or peripheral blood samples, so as to assist in judging the clinical prognosis of patients with acute myeloid leukemia.

The invention discloses a method for detecting non-target cells in amniotic epithelial cells, which comprises reagents for detecting one or more of the following gene markers: FCGBP, RNASE6, DAB2, STAB1, RAB3IL1, CSF1R, CD68, CD209, EGFL7, LGALS2, LILRB4, HLA-DMB, HLADMA, CD74, ANPEP, CD44, CCR7, CD3G, CD3D, CD27, CD5, SPOCK2, TCF7, GZMH, KLRC2 and the like. Wherein the non-target cells are selected from macrophage-like cells, monocyte-like cells, T cell-like cells, NK cell-like cells, myeloid-like cells and neutrophil-like cells, a detection method is provided for quality control of the amniotic epithelial cells, and guidance is also provided for a cell product preparation process.

The present invention relates to the field of antibody technology, and more particularly to an antibody that specifically recognizes CD14 and its application in nanomagnetic bead sorting. The anti-CD14 antibody of the present invention can specifically recognize and bind to human CD14 without cross-reacting with other cell surface antigens such as CD8, CD11, CD68, CD195, etc.; the antibody has a high affinity for human CD14 and can be used as a detection antibody for CD14, and can also be used as a CD14 detection antibody. + Cell sorting antibodies achieve high purity CD14 + Efficient preparation of cells or for depletion of CD14 in CAR-T cell products + Cells can be used to improve the purity and quality of CAR-T cells, and have good application prospects in immune cell preparation and quality control.

Disclosed is an application of a mechanical force sensitive macrophage subset in pancreatic cancer diagnosis or prognosis evaluation, in which it is found that a number of mechanical force sensitive macrophages of CD68+p-PYK2+YAP1+ in pancreatic cancer is obviously higher than that of an adjacent normal tissue, and the number of the macrophages is in positive correlation with a pancreatic cancer process, so that the mechanical force sensitive macrophages can be used as a pancreatic cancer diagnosis and prognosis index. An elasticity modulus of the cells is reduced by inhibiting a mechanical force check point PYK2 of monocytes / macrophages, and differentiation of the monocytes into the macrophages is inhibited, so that a tumor micro-environment of the pancreatic cancer is improved. Growth of the pancreatic cancer is remarkably inhibited through combined treatment, and the lifetime of mice with the pancreatic cancer is remarkably prolonged.

The invention relates to the technical field of biology, and discloses a kit for predicting clinical pregnancy outcome of first-time frozen embryo transplantation. The kit comprises immune cells and immune factors in blood, the immune cells comprise CD19 < + > B cells, CD3 < + > T cells, CD4 < + > Th cells, CD8 < + > Ts cells, CD4 < + > / CD8 < + > ratio cells, CD56 < + > NK cells, CD68 < + > monocytes, CD86 < + > M1 sample monocytes, D206 < + > M2 sample monocytes and CD163 < + > M2 sample monocytes; the immune factors comprise IL-1beta, IL-2r, IL-6, IL-8 and TNF (Tumor Necrosis Factor)-alpha. According to the application, the importance of the peripheral blood CD163 + M2 sample mononuclear cell on predicting the continuous pregnancy of first embryo implantation of an FE T patient is confirmed, and the peripheral blood CD163 + M2 sample mononuclear cell is prompted to be possibly a biomarker of an FET period.

Methods and compositions for PCR based means for generating gene-signature based risk scores for the prognosis of breast cancer recurrence and predicting therapy efficacy. The invention uses competitive amplification of 21 genes to encode the gene signature into the design of the oligonucleotides, making downstream amplification and subsequent analysis straight forward and suitable to be performed on-site. The 21 genes comprise the housekeeping module: ACTB, GAPDH, GUSB, RPLP0, and TFRC; the invasion module: CD68, CTSV, MMP11; the proliferation module: AURKA, BIRC5, CCNB1, MKI67, MYBL2; the HER2 module: ERBB2, and GRB7; and the Estrogen module; BAG1, BCL2, ESR1, GSTM1, PGR, and SCUBE2.

The invention discloses application of an mRNAs marker in early diagnosis of lung signet-ring cell carcinoma and a kit. The marker is a combination of C1QA, CRISPLD2, ROBO4, SPARCL1, SFTPB, LAMC3, FN1, EMP1, CD68, THBS1, PRG4, ICAM1, PODXL, KDM6B, ENPP2, KLF10 and THBD (tetrahydrofuran). According to the invention, FFPE cancer tissue of a patient with primary pulmonary signet ring cell carcinoma diagnosed by an existing detection means in clinic is used as a sample, para-carcinoma tissue is used as a control sample, mRNA expression profiles of the cancer tissue and the control tissue are detected by adopting an RNA sealing technology, and 17 differentially expressed mRNA markers are found by applying statistics and a machine learning method. Based on the 17 found markers, a risk scoring model with high sensitivity and specificity is constructed, and the sensitivity gt of the model to early-stage lung signet-ring cell carcinoma diagnosis; the specificity is gt; 89%.

The application belongs to the technical field of medical treatment and discloses a cancer prognosis marker combination and application thereof, which comprises the following markers: CD68, PD-L1, PAN-CK, HLA-DR, CD45, CD11c and Collagen I. The cancer prognosis evaluation model trained by using the 7-marker combination exhibits superior prognosis accuracy compared to a model relying on high-dimensional multi-omics data. The application proposes a multiple immunohistochemistry (mIHC) cancer prognosis evaluation detection product based on the above-mentioned cancer prognosis marker combination. Satisfactory prognosis results are achieved by using only two five-marker combinations. The method exhibits high accuracy in predicting the survival of gastric cancer patients, so that it becomes a low-cost, high-benefit and scalable solution for other cancers.

The invention belongs to the technical field of biology, and particularly relates to a marker for prognosis evaluation of acute myelogenous leukemia and application of the marker, the marker is HCK-positive mono-like cells, and the HCK-positive mono-like cells are determined when an antigen CD163, an antigen CD68, an antigen FCN1 and an antigen HCK are co-positive. The kit is used for detecting bone marrow or peripheral blood samples of adult acute myelogenous leukemia so as to assist in judging clinical prognosis conditions of patients with acute myelogenous leukemia.

The invention discloses a kit for evaluating the uridine metabolic activity and prognosis of the tumor microenvironment of a lung cancer patient, the kit comprises a UPP1 antibody, an EPCAM antibody, a CD68 antibody and a CD66b antibody which are labeled by different fluorescence, the UPP1 antibody is combined with a green fluorescent dye Alexa Fluor 488, the EPCAM antibody is combined with a red fluorescent dye Alexa Fluor 594, the CD68 antibody is combined with a blue fluorescent dye Alexa Fluor 650, and the CD66b antibody is combined with a yellow fluorescent dye Alexa Fluor 555. According to the kit, the expression level of UPP1 in tumor cells and immune cells is detected, cell specific markers EPCAM, CD68 and CD66b are combined for quantitatively evaluating the metabolic activity of uridine in the tumor microenvironment and prognostic metabolic activity, and a scientific basis is provided for early diagnosis and prognostic evaluation of lung cancer.

The invention discloses an application of TRAF7 in screening of anti-lung injury drugs. In an LPS-induced A549 cell acute lung injury model, TRAF7 gene knock-down significantly aggravates cell apoptosis and inflammatory response, which shows that inflammatory factor release is increased, and cell injury is aggravated; and TRAF7 overexpression can obviously inhibit the pathological change. The result shows that the TRAF7 has a protection effect on alveolar epithelial cells, the expression level of the TRAF7 is in negative correlation with the in-vitro lung injury degree, and it is proved that the TRAF7 has a negative regulation effect in acute lung injury. In a mouse ALI model, TRAF7 overexpression can significantly reduce the total number of cells, the total protein content and the wet / dry weight ratio of lung tissue in bronchoalveolar lavage fluid (BALF), relieve the pathological injury score of the lung and inhibit LY6Gneutrophil and CD68 macrophage infiltration. The TRAF7 can effectively relieve LPS-induced pulmonary edema, vascular permeability increase and tissue inflammation, and the anti-inflammatory and tissue protection functions of the TRAF7 in an in-vivo model are verified.

This application relates to the technical field of biological detection, and specifically discloses an anti-rHPV68 L1 protein CD68 monoclonal antibody and a detection kit for rHPV68 type protein antigen. This application discloses an anti-rHPV68 L1 protein CD68 monoclonal antibody, and the DNA sequence of the anti-rHPV68 L1 protein CD68 monoclonal antibody is shown as SEQ ID NO.1. Using the above anti-rHPV68 L1 protein CD68 monoclonal antibody, this application provides a TRFIA detection kit for the content of rHPV68 type protein antigen. When using this TRFIA detection kit to detect the content of rHPV68 type protein antigen, it has strong specificity, and the sensitivity, accuracy and precision of this detection method are relatively high.

The invention provides application of an adeno-associated virus overexpressing CTH in preparation of drugs for extravascular treatment of abdominal aortic aneurysm. When the adeno-associated virus overexpressing CTH is applied to the periphery of abdominal aortic aneurysm, fracture of elastic fibers of abdominal aorta can be reduced, collagen deposition can be reduced, infiltration of macrophages (CD68) can be reduced, secretion of matrix metalloproteinase can be reduced, degradation of extracellular matrixes can be reduced, and occurrence and development of AAA can be relieved.

The invention belongs to the technical field of medical treatment, and discloses a cancer prognosis marker combination and application thereof, and the cancer prognosis marker combination comprises the following markers: CD68, PD-L1, PAN-CK, HLA-DR, CD45, CD11c and Collagen I. Compared with a model depending on high-dimensional multi-omics data, a cancer prognosis evaluation model obtained by combined training of the seven markers shows more excellent prognosis accuracy. The invention provides a mIHC (multiple immunohistochemical) cancer prognosis evaluation and detection product based on the cancer prognosis marker combination. And a satisfactory prognosis result can be obtained only by using the combination of two five markers. The method shows relatively high accuracy in the aspect of predicting the survival of the gastric cancer patient, so that the method becomes a solution which is low in cost and high in benefit and can be expanded to other cancers.

In the present invention, the mRNA of CXCL5, CD68, MATN1, SERPING1, SNCG, VTN, FBXO4, and SYTL4 genes, or the proteins encoded by these genes, exhibit differential expression levels between radioresistant and radiosensitive colorectal cancer cells, and are closely correlated with reduced survival rates in colorectal cancer patients. Therefore, an agent for measuring the expression levels of the mRNA of the genes selected from the group consisting of CXCL5, CD68, MATN1, SERPING1, SNCG, VTN, FBXO4, and SYTL4 or the proteins encoded by the genes according to the present invention effectively diagnoses radio-resistance in colorectal cancer or prognoses radiotherapy for colorectal cancer. This enables the determination of whether to proceed with radiotherapy and the optimal radiation dose, thereby improving the efficiency and outcomes of radiotherapy for colorectal cancer.

Disclosed is an application of a mechanical force sensitive macrophage subset in pancreatic cancer diagnosis or prognosis evaluation, in which it is found that a number of mechanical force sensitive macrophages of CD68+p-PYK2+YAP1+ in pancreatic cancer is obviously higher than that of an adjacent normal tissue, and the number of the macrophages is in positive correlation with a pancreatic cancer process, so that the mechanical force sensitive macrophages can be used as a pancreatic cancer diagnosis and prognosis index. An elasticity modulus of the cells is reduced by inhibiting a mechanical force check point PYK2 of monocytes / macrophages, and differentiation of the monocytes into the macrophages is inhibited, so that a tumor micro-environment of the pancreatic cancer is improved. Growth of the pancreatic cancer is remarkably inhibited through combined treatment, and the lifetime of mice with the pancreatic cancer is remarkably prolonged.

The application relates to the field of biological medicine, in particular to an anti-CD68 antibody and preparation and application thereof, wherein the anti-CD68 antibody has heavy chain complementarity determining regions 1-3 as shown in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 respectively, and light chain complementarity determining regions 1 and 3 as shown in SEQ ID NO:4 and SEQ ID NO:5 respectively, and a light chain complementarity determining region 2 with LVS. Compared with the CD68 antibody proposed in the related art, the anti-CD68 antibody proposed in the application has stronger binding specificity to CD68 and lower reaction background, thereby realizing high-accuracy detection of CD68.

The invention discloses an application of a bone marrow SELENOP positive macrophage and a GAS6-AXL axis in bone marrow hematopoiesis regulation and control. The invention provides a bone marrow SELENOP + macrophage (the immunophenotype is CD14 + CD68 + SELENOP +) and an application of the macrophage in diagnosing whether a subject has a potential risk of hematopoietic injury or not. The invention also provides an application of a substance capable of activating a GAS6-AXL signal axis in preparation of a product for treatment or adjuvant treatment of bone marrow hematopoietic injury diseases. The novel bone marrow SELENOP + macrophage subgroup identified by the invention is of great significance to reveal a new subtype of bone marrow macrophages and the effect of the bone marrow macrophages in promoting normal bone marrow hematopoietic reconstruction, and is helpful to further explore a new target for treating bone marrow hematopoietic injury diseases; therefore, the method is beneficial to patients with implantation malfunction and other bone marrow hematopoietic injury diseases.

The present disclosure relates to methods of treating certain cancers with a Siglec-9 extracellular domain (ECD) or a Siglec-9 ECD fusion molecule, including cancers expressing high levels of CD163 and / or Siglec-9 in tumor or immune cells, and methods of identifying cancers responsive to a Siglec-9 ECD or Siglec-9 ECD fusion molecule, for example by determining the level of CD163 and / or Siglec-9, and in some embodiments also CD68 and / or sialic acid expression in tumor or immune cells.

A use of a mechanical force-responsive macrophage subgroup in diagnostic or prognostic estimation for pancreatic cancer. The number of mechanical force-responsive macrophages CD68+p-PYK2+YAP1+ in pancreatic cancer is significantly higher than that in paracancerous tissue, and the number of such macrophages is positively correlated with the progression of pancreatic cancer. Therefore, the mechanical force-responsive macrophages can be used as diagnostic and prognostic indicators for pancreatic cancer. Inhibition of a mechanical force checkpoint PYK2 for monocytes / macrophages can reduce the elastic moduli of cells and inhibit the differentiation of monocytes to macrophages, so that the tumor microenvironment of pancreatic cancer is improved. Targeted inhibition, regulation and control of the mechanical force checkpoint PYK2 for monocyte / macrophage differentiation, in combination with combined treatment such as the treatment for an immune checkpoint PD-1, can significantly inhibit the growth of pancreatic cancer, and significantly prolong the survival periods of mice with pancreatic cancer.

The invention discloses a prognostic marker for bladder cancer and application of the prognostic marker. The prognostic marker for the bladder cancer comprises CD14T, CD68S, CD163T and S100A12S; wherein the CD14T and the CD163T respectively refer to CD14 and CD163 expressed in a bladder cancer tumor region, and the CD68S and the S100A12S respectively refer to CD68 and S100A12 expressed in a bladder cancer matrix region. The bladder cancer prognosis marker provided by the invention can be used for constructing a bladder cancer prognosis prediction model, and multi-queue verification proves that the model has a strong prediction capability on the postoperative survival condition of a BLC patient and is beneficial to postoperative risk assessment and clinical decision of the BLC patient.

The invention provides application of an adeno-associated virus overexpressing CBX3 in preparation of a medicine for extravascular treatment of abdominal aortic aneurysm. When the adeno-associated virus overexpressing CBX3 is applied to the periphery of abdominal aortic aneurysm, fracture of elastic fibers of abdominal aorta can be reduced, collagen deposition can be reduced, infiltration of macrophages (CD68) can be reduced, secretion of matrix metalloproteinase can be reduced, degradation of extracellular matrixes can be reduced, and occurrence and development of AAA can be relieved.

The application relates to the field of biotechnology and relates to immune monitoring and imaging, and particularly discloses a base editing ectopic kidney method and a spatial omics imaging monitoring method. The base editing ectopic kidney method comprises the following steps: extracting and screening cytidine deaminase conditional knockout engineered cells of base editing conditional knockout young mice; the cytidine deaminase conditional knockout engineered cells are implanted into a spontaneous immune disease mouse model characterized by nephritis, and an autoimmune-kidney generation model is established. The young mice of APOBEC3 base editing enzyme CD68 cell conditional knockout mice are used as a functional cell source, the cytidine deaminase is not translated, the young mice are suitable for ectopic kidney generation, and the time cost required by single cell amplification, breeding and screening in a traditional cell transplantation scheme is avoided, and the experimental process is greatly simplified.

The invention discloses application of CD44v9 positive M2 type macrophages in preparation of gastric adenocarcinoma diagnosis or treatment products, in the technical scheme provided by the invention, it is proved that the M2 type macrophages of CD68 + CD86-CD163 + can express CD44v9 through multiple fluorescent staining, human acute mononuclear leukemia cells (THP-1 cells) are subjected to in-vitro culture and are sequentially induced into M0 type macrophages and M2 type macrophages, and the M0 type macrophages and the M2 type macrophages can be used for diagnosing or treating gastric adenocarcinoma. Then, the expression conditions of the M0 type macrophage CD44v9 and the M2 type macrophage CD44v9 are observed, and the result shows that the M0 type macrophage and the M2 type macrophage which are induced by the THP-1 cell in vitro can express the CD44v9, and the expression level of the M2 type macrophage is higher than that of the M0 type macrophage CD44v9. Afterwards, after co-culture with gastric adenocarcinoma AGS cells in M2 macrophages infected and induced by over-expressed CD44v9 lentivirus, the proliferation, migration and invasion capabilities of the AGS cells are enhanced, and the epithelial-mesenchymal transition of the AGS cells and the expression of matrix metalloproteinases (MMP2 and MMP9) are promoted.